Antifibrillatory properties of the beta-adrenergic receptor antagonists, nadolol, sotalol, atenolol and propranolol, in the anesthetized dog
- PMID: 6144114
- DOI: 10.1159/000137953
Antifibrillatory properties of the beta-adrenergic receptor antagonists, nadolol, sotalol, atenolol and propranolol, in the anesthetized dog
Abstract
The antifibrillatory and electrophysiologic actions of the beta-adrenergic receptor antagonists, d,l-sotalol, d,l-nadolol, d,l-atenolol and d,l-propranolol were examined in anesthetized dogs. All four drugs were equally effective in increasing the electrical threshold for induction of ventricular fibrillation, but efficacy failed to correlate with reported beta-blocking efficacy. The d-isomers of the respective beta-adrenergic receptor blocking agents, sotalol and propranolol, were equipotent and equally effective at increasing the fibrillation threshold compared to their respective racemates. The ability of beta-adrenergic antagonists to increase the fibrillation threshold could not be attributed to changes in intraventricular conduction, ventricular refractoriness, or ventricular excitability in common with all four drugs. The antifibrillatory actions of the beta-adrenergic receptor blocking drugs could not be attributed solely to either beta-adrenergic blockade or specific alterations in the membrane properties of the cardiac cell.
Similar articles
-
Interactions of beta-adrenoceptor antagonists and thyroid hormones in the control of heart rate in the dog.Br J Pharmacol. 1985 Oct;86(2):393-8. doi: 10.1111/j.1476-5381.1985.tb08908.x. Br J Pharmacol. 1985. PMID: 2864972 Free PMC article.
-
Evaluation of the antifibrillatory activity of fluorinated derivatives of indenolol and nadolol in isolated rabbit and rat hearts: comparison with propranolol.Arch Int Pharmacodyn Ther. 1989 Sep-Oct;301:122-30. Arch Int Pharmacodyn Ther. 1989. PMID: 2576192
-
Class III action of beta-blocking agents.Cardiovasc Res. 1984 Nov;18(11):683-9. doi: 10.1093/cvr/18.11.683. Cardiovasc Res. 1984. PMID: 6149809
-
Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.Eur Heart J. 1993 Nov;14 Suppl H:14-23. doi: 10.1093/eurheartj/14.suppl_h.14. Eur Heart J. 1993. PMID: 7904934 Review.
-
Symposium on the management of ventricular dysrhythmias. Antifibrillatory versus antiectopic therapy.Am J Cardiol. 1984 Jul 30;54(2):7A-13A. doi: 10.1016/0002-9149(84)90811-7. Am J Cardiol. 1984. PMID: 6147079 Review.
Cited by
-
Anion and cation modulation of the guinea-pig ventricular action potential during beta-adrenoceptor stimulation.Pflugers Arch. 1993 Jun;424(1):54-62. doi: 10.1007/BF00375102. Pflugers Arch. 1993. PMID: 8394573
-
Pharmacodynamic, pharmacokinetic and antiarrhythmic properties of d-sotalol, the dextro-isomer of sotalol.Drugs. 1995 May;49(5):664-79. doi: 10.2165/00003495-199549050-00003. Drugs. 1995. PMID: 7601009 Review.
-
Adrenergic Blockade Bi-directionally and Asymmetrically Alters Functional Brain-Heart Communication and Prolongs Electrical Activities of the Brain and Heart during Asphyxic Cardiac Arrest.Front Physiol. 2018 Feb 13;9:99. doi: 10.3389/fphys.2018.00099. eCollection 2018. Front Physiol. 2018. PMID: 29487541 Free PMC article.
-
Sotalol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.Drugs. 1987 Sep;34(3):311-49. doi: 10.2165/00003495-198734030-00002. Drugs. 1987. PMID: 3315621 Review.
-
Effect of propranolol on ventricular repolarization and refractoriness: role of beta-blockade versus direct membrane effects.Cardiovasc Drugs Ther. 1988 Mar;1(6):605-12. doi: 10.1007/BF02125746. Cardiovasc Drugs Ther. 1988. PMID: 2908700
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources